Skip to main content

Table 1 Baseline characteristics and pulse wave analysis

From: Augmentation index is associated with coronary revascularization in patients with high Framingham risk scores: a hospital-based observational study

 

PCI group

Non-PCI group

p

 

n = 73 (%)

n = 159 (%)

 

Male

50 (68.5)

97 (61.0)

0.306

Age (years)

64.8 ± 10.3

59.6 ± 13.1

0.001

Height (cm)

163.8 ± 7.7

163.0 ± 8.5

0.486

Body weight (Kg)

66.9 ± 11.4

68.2 ± 11.4

0.442

Body mass index (kg/m2)

24.8 ± 3.5

25.6 ± 3.2

0.085

Brachial systolic pressure (mmHg)

148.9 ± 22.4

144.1 ± 22.6

0.135

Brachial diastolic pressure (mmHg)

87.0 ± 11.0

85.1 ± 10.5

0.203

Brachial pulse pressure (mmHg)

61.8 ± 17.6

58.7 ± 17.6

0.216

CVD risk points

18.6 ± 4.0

14.9 ± 5.4

<0.001*

10-year estimate of CVD risk (%)

25.3 ± 6.5

18.8 ± 10.2

<0.001*

Diabetes

20 (27.4)

33 (20.8)

0.312

Hypertension

53 (72.6)

78 (49.1)

0.001

Hyperlipidemia

34 (46.6)

46 (28.9)

0.011

Total cholesterol (mg/dL)

181.1 ± 45.6

185.9 ± 54.0

0.513

HDL cholesterol (mg/dL)

41.0 ± 11.2

46.0 ± 12.3

0.002*

Smoking

24 (32.9)

40 (25.2)

0.268

Left ventricular ejection fraction (n = 111)

59.0 ± 14.5

65.3 ± 10.1

0.036

Central pulse pressure (mmHg)

53.4 ± 17.1

49.4 ± 18.0

0.110

Augmented pressure (mmHg)

20.3 ± 9.5

16.9 ± 8.8

0.009

Augmentation index (%)

36.5 ± 9.3

32.5 ± 10.0

0.004

Augmentation index @75 (%)

31.6 ± 8.5

27.2 ± 9.0

0.006**

  1. CVD cardiovascular disease, HDL high-density lipoprotein, PCI percutaneous coronary intervention, Data are expressed as means ± standard deviation or numbers (percentage); chi-square test or Wilcoxon two-sample test (or Mann–Whitney U test)
  2. *p value for comparison between the PCI (n = 70) and non-PCI (n = 146); p < 0.05 considered significant
  3. **ANCOVA test: adjusting for ejection fraction (n = 111)